PL2215047T3 - Sposób leczenia niedoborów witaminy b12 - Google Patents

Sposób leczenia niedoborów witaminy b12

Info

Publication number
PL2215047T3
PL2215047T3 PL08844673T PL08844673T PL2215047T3 PL 2215047 T3 PL2215047 T3 PL 2215047T3 PL 08844673 T PL08844673 T PL 08844673T PL 08844673 T PL08844673 T PL 08844673T PL 2215047 T3 PL2215047 T3 PL 2215047T3
Authority
PL
Poland
Prior art keywords
deficiency
treating vitamin
vitamin
treating
Prior art date
Application number
PL08844673T
Other languages
English (en)
Polish (pl)
Inventor
Cristina Castelli
Laura Kragie
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2215047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of PL2215047T3 publication Critical patent/PL2215047T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08844673T 2007-11-02 2008-10-31 Sposób leczenia niedoborów witaminy b12 PL2215047T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US2010808P 2008-01-09 2008-01-09
US8356608P 2008-07-25 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency
EP08844673.7A EP2215047B1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
PL2215047T3 true PL2215047T3 (pl) 2014-05-30

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08844673T PL2215047T3 (pl) 2007-11-02 2008-10-31 Sposób leczenia niedoborów witaminy b12

Country Status (18)

Country Link
US (3) US8022048B2 (enExample)
EP (1) EP2215047B1 (enExample)
JP (1) JP5555634B2 (enExample)
KR (1) KR101344369B1 (enExample)
CN (1) CN101952241B (enExample)
AU (1) AU2008318423B2 (enExample)
BR (1) BRPI0817396C8 (enExample)
CA (1) CA2704780C (enExample)
CL (1) CL2010000434A1 (enExample)
CO (1) CO6280475A2 (enExample)
DK (1) DK2215047T3 (enExample)
ES (1) ES2443817T3 (enExample)
MX (1) MX2010004716A (enExample)
NZ (1) NZ585080A (enExample)
PL (1) PL2215047T3 (enExample)
PT (1) PT2215047E (enExample)
RU (1) RU2469728C2 (enExample)
WO (1) WO2009059188A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985985B2 (ja) * 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． 胃腸への影響が減少した即効型ナプロキセン組成物
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 ｂ12 치료요법
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
EP2696687B1 (en) 2011-04-12 2016-10-26 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
MX382853B (es) 2016-04-22 2025-03-13 Spoke Sciences Inc Compuestos medicinales y suplementos nutricionales de base vegetal de rápida acción.
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20200254041A1 (en) * 2017-10-05 2020-08-13 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
US20200268821A1 (en) * 2017-10-05 2020-08-27 Receptor Holdings, Inc. Herbal compositions with improved bioavailability
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
MXPA01006297A (es) * 1998-12-28 2002-06-04 Biogentec Inc Tratamiento con cianocobalamina (vitamina b12) para enfermedades alergicas.
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
JP4799794B2 (ja) * 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2446929C (en) 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
JP4959917B2 (ja) 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
EP1545477A4 (en) 2002-09-13 2006-11-22 Cydex Inc CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
WO2005004900A1 (en) * 2003-07-11 2005-01-20 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US7749954B2 (en) 2003-07-23 2010-07-06 Novartis Ag Use of calcitonin in osteoarthritis
JP4903690B2 (ja) * 2004-05-06 2012-03-28 エミスフェアー・テクノロジーズ・インク Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体
WO2006020291A2 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CA2626029A1 (en) * 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods

Also Published As

Publication number Publication date
MX2010004716A (es) 2010-12-17
KR20100126263A (ko) 2010-12-01
AU2008318423B2 (en) 2013-12-05
CA2704780A1 (en) 2009-05-07
EP2215047A1 (en) 2010-08-11
BRPI0817396C1 (pt) 2020-11-17
US8288360B2 (en) 2012-10-16
JP5555634B2 (ja) 2014-07-23
HK1146480A1 (en) 2011-06-10
AU2008318423A1 (en) 2009-05-07
US8557792B2 (en) 2013-10-15
CN101952241B (zh) 2014-06-11
RU2469728C2 (ru) 2012-12-20
BRPI0817396C8 (pt) 2021-05-25
BRPI0817396B8 (pt) 2020-02-04
PT2215047E (pt) 2014-01-20
CO6280475A2 (es) 2011-05-20
US8022048B2 (en) 2011-09-20
CN101952241A (zh) 2011-01-19
CL2010000434A1 (es) 2011-01-28
DK2215047T3 (da) 2014-02-03
BRPI0817396A2 (pt) 2015-04-07
JP2011502997A (ja) 2011-01-27
ES2443817T3 (es) 2014-02-20
NZ585080A (en) 2012-05-25
US20110293589A1 (en) 2011-12-01
KR101344369B1 (ko) 2013-12-24
EP2215047A4 (en) 2010-11-10
RU2010118423A (ru) 2011-12-10
WO2009059188A1 (en) 2009-05-07
EP2215047B1 (en) 2013-11-20
US20100016255A1 (en) 2010-01-21
BRPI0817396B1 (pt) 2019-04-24
US20130040910A1 (en) 2013-02-14
CA2704780C (en) 2014-06-10

Similar Documents

Publication Publication Date Title
PT2215047E (pt) Processo para o tratamento da deficiência de vitamina b12
PL2148684T3 (pl) Sposób leczenia niedoboru i deficytu witaminy D
IL257418A (en) Methods for treating addiction
IL212348A0 (en) Treatment method
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL227641A0 (en) Methods for treating arthritis
ZA201707693B (en) Vitamin d3 and analogs thereof for treating alopecia
EP2148685A4 (en) METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
PL2301893T3 (pl) Sposób oczyszczania ścieku
IL200499A0 (en) Stabilization of vitamin b12
EP2144504A4 (en) METHOD FOR COMBATING BRAIN CANCER
EP2350641A4 (en) Methods of Treatment
IL200769A (en) A method for processing potash
IL238394A0 (en) Cancer treatment method
PT2393758E (pt) Processo de tratamento de águas residuais
GB0718684D0 (en) Treatment method
EP2144886A4 (en) METHOD OF TREATING MELANOMA
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
PT2509599E (pt) Processo para o tratamento de cancro pancreático
EP2203432A4 (en) PROCESSING METHOD
GB0723972D0 (en) Use of vitamin B12
GB0717337D0 (en) Method of treatment
GB0711228D0 (en) Treatment method
ZA201102198B (en) Treatment method
GB0823435D0 (en) Method of treatment